A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer

Inhibitory antibodies targeting programmed death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) have resulted in improved outcomes for many patients with metastatic non-small cell lung cancer in (NSCLC) in the second-line setting due to their ability to lead to prolonged anti-tumor immune re...

Descripción completa

Detalles Bibliográficos
Autores principales: Pacheco, Jose M., Camidge, D. Ross, Doebele, Robert C., Schenk, Erin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450209/
https://www.ncbi.nlm.nih.gov/pubmed/30984621
http://dx.doi.org/10.3389/fonc.2019.00195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450209/
https://www.ncbi.nlm.nih.gov/pubmed/30984621
http://dx.doi.org/10.3389/fonc.2019.00195

Ejemplares similares